专题：专题|2024年度A股董秘数据报告：1144位董秘年薪超百万 占比超21% 董秘作为连接投资者与上市公司的"桥梁"，在上市公司资本运作中发挥着关键作用。新浪财经《2024年 度A股董秘数据报告》显示，2024年A股上市公司董秘薪酬合计达40.86亿元，平均年薪75.43万元。 分行业来看，统计数据显示，剔除未任职2024年全年董秘数据后，A股共有110家上市化学制剂公司， 其聘任总体情况如下（部分统计口径剔除无效数据）。 从董秘的年龄分布来看，40岁-50岁董秘是市场的中坚力量，占比共计达到46%；50岁以上的董秘占比 为21%；小于或等于40岁的董秘群体占比为33%。其中，目前仍任职的最年轻的男上市公司董秘年龄31 岁，为莎普爱思的黄明雄；最年轻的女董秘年龄为33岁，为百利天恒的陈英格。 从董秘的学历分布看，拥有专科、本科、硕士、博士学历的董秘占比分别为7%、37%、50%、6%。其 中，获得博士学历的董秘共6人，分别为舒泰神的于茂荣、人福医药（维权）的李前伦、灵康药业（维 权）的隋国平、海正药业的沈锡飞、益方生物-U的江岳恒、健友股份的黄锡伟。其中，海正药业的沈 锡飞为行业唯一一个拥有博士学历的专职 ...

Core Viewpoint - DZD8586, developed by the company, has received Fast Track Designation from the FDA for the treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in patients who have undergone at least two lines of treatment, including BTK inhibitors and BCL-2 inhibitors [1][2] Group 1 - DZD8586 is a first-in-class dual-target inhibitor that simultaneously blocks both BTK-dependent and independent BCR signaling pathways, addressing two major resistance mechanisms in CLL/SLL [1] - The drug has shown a high objective response rate (ORR) of 84.2% in patients previously treated with various therapies, including BTK inhibitors and BCL-2 inhibitors, with a duration of response (DOR) rate of 83.3% expected at 9 months [2] - The Fast Track Designation allows for expedited drug development and review processes, facilitating quicker access to new therapies for serious diseases with unmet medical needs [2]

Group 1: Policy and Regulatory Developments - The Shanghai regulatory authorities issued 18 measures to promote the high-quality development of commercial health insurance, focusing on expanding coverage to include new medical technologies and services [1] - The National Medical Products Administration is seeking public opinion on the draft guidelines for the quality management of medical device online sales, aiming to standardize inspection practices [2] Group 2: Company Announcements and Developments - Heng Rui Medicine announced that its product, injection of Rui Kang Qu Mo Zhu single antibody, received orphan drug designation from the FDA, which may provide policy support for its development and commercialization [3] - Di Zhe Medicine received Fast Track Designation from the FDA for its innovative drug DZD8586, aimed at treating relapsed refractory chronic lymphocytic leukemia [4] - Tuo Jing Life Sciences' subsidiary obtained two medical device registration certificates for diagnostic kits, enhancing its competitiveness in the in vitro diagnostic field [5] - Sino Medical's subsidiary received breakthrough medical device designation from the FDA for its intracranial drug-coated stent system, marking a significant achievement in domestic neurointerventional devices [6] Group 3: Financial Performance - BeiGene reported a net profit of 450 million yuan for the first half of 2025, marking a turnaround with a 45.8% increase in product revenue [7] - Tian Tan Biology's net profit decreased by 12.88% year-on-year, despite a 9.47% increase in total revenue, attributed to declining product prices and reduced interest income [8] Group 4: Investment Activities - Pian Zai Huang plans to invest 200 million yuan in the Gao Xin Run Xin Fund, which targets a total fundraising goal of 1 billion yuan, reflecting the company's strategy in the health industry [9] Group 5: Industry Collaborations - Jing Tai Technology and DoveTree established a collaboration worth 47 billion HKD for AI drug development, setting a new record in the AI pharmaceutical sector [10] Group 6: Shareholder Actions - Qian Hong Pharmaceutical announced plans for shareholders to reduce their holdings by up to 20.9 million shares, representing 1.63% of the total share capital [11] - Shu Yu Ping Min's controlling shareholder plans to reduce their stake by up to 2%, amounting to 804,730 shares [12]

Policy Developments - Shanghai has introduced 18 measures to promote the high-quality development of commercial health insurance, focusing on expanding coverage to include new medical technologies, drugs, and devices [1] Drug and Device Approvals - Heng Rui Medicine's injection of Rukang Qutuo Zhun Tan has received orphan drug designation from the FDA for use in gastric cancer, which had 968,400 new cases globally in 2022 [3] - DIZHE Pharmaceutical's DZD8586, a dual-target inhibitor, has received Fast Track Designation from the FDA for treating relapsed chronic lymphocytic leukemia [4] - Sainuo Medical's subsidiary has received breakthrough device designation from the FDA for its self-expanding intracranial drug-coated stent system, marking a first for domestic neuro-interventional devices [7] Financial Reports - BeiGene reported a net profit of 450 million yuan for the first half of 2025, reversing losses from the previous year, with product revenue increasing by 45.8% to 17.36 billion yuan [8] - Tiantan Biological's net profit for the first half of 2025 decreased by 12.88% to 633 million yuan, attributed to declining product prices and reduced interest income [9] Capital Market Activities - Pianzaihuang plans to invest 200 million yuan in the Gao Xin Run Xin Fund, which aims to raise 1 billion yuan, representing 20% of the fund's target size [10] Industry Developments - Jingtai Technology has entered a 47 billion HKD collaboration with DoveTree for AI drug development, setting a new record in the AI pharmaceutical sector [11] Shareholder Actions - Qianhong Pharmaceutical's shareholder plans to reduce holdings by up to 20.9 million shares, representing 1.63% of the total share capital [11] - Shuyupingmin's controlling shareholder intends to reduce holdings by up to 804,730 shares, accounting for 2% of the total share capital [12]

Group 1: Company Performance - BeiGene reported a net profit of 450 million yuan for the first half of 2025, marking a turnaround from losses in the previous year, with product revenue increasing by 45.8% to 17.36 billion yuan and total revenue rising by 46.0% to 17.52 billion yuan [1] - CITIC Securities announced that Huaxia Fund achieved an operating income of 4.258 billion yuan and a net profit of 1.123 billion yuan in the first half of 2025, with total comprehensive income of 1.106 billion yuan [3] - Shanghai Pudong Development Bank's net profit for the first half of 2025 was 29.737 billion yuan, reflecting a year-on-year growth of 10.19%, with total operating income of 90.559 billion yuan, up 2.62% [6] - Xianhe Co. plans to invest approximately 11 billion yuan in a new integrated high-performance paper-based material project, with an expected annual output value of about 5.15 billion yuan from the first phase [7] - Shengmei Shanghai reported a net profit of 696 million yuan for the first half of 2025, representing a year-on-year increase of 56.99% [14] Group 2: Regulatory and Corporate Actions - Sino Medical's subsidiary received breakthrough medical device designation from the FDA for its intracranial atherosclerosis treatment product, marking it as the first of its kind globally [2] - *ST Dongtong's actual controller and chairman is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws [8] - Tianyang Technology is planning to purchase equity in Tonglian Financial Services, with key transaction details still under negotiation [10] - Dongfang Guoxin's major shareholder reduced their stake by 2.68 million shares, decreasing their total shareholding from 27.06% to 26.82% [5] - Filinger's president reduced his holdings by 8,600 shares during a period of stock price volatility, while other executives did not sell shares [4]

Group 1: Company Performance - BeiGene reported a net profit of 450 million yuan for the first half of 2025, marking a turnaround from losses in the previous year, with product revenue increasing by 45.8% to 17.36 billion yuan and total revenue rising by 46.0% to 17.52 billion yuan [1] - CITIC Securities announced that Huaxia Fund achieved a net profit of 1.123 billion yuan in the first half of 2025, with total operating income of 4.258 billion yuan and total comprehensive income of 1.106 billion yuan [1] - Shanghai Pudong Development Bank reported a net profit of 29.737 billion yuan for the first half of 2025, reflecting a year-on-year growth of 10.19%, with total operating income of 90.559 billion yuan, up 2.62% [4] - Xianhe Co., Ltd. plans to invest approximately 11 billion yuan in a new integrated high-performance paper-based material project, with an expected annual output value of about 5.15 billion yuan from the first phase [5] - Shunbo Alloy reported a net profit growth of 110.56% year-on-year for the first half of 2025 [12] Group 2: Regulatory and Corporate Actions - Sino Medical announced that its subsidiary received breakthrough medical device designation from the FDA for a new intracranial atherosclerosis treatment product, marking a significant milestone as the first of its kind globally [1] - *ST Dongtong's actual controller and chairman is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws [6][7] - Tianyang Technology is planning to purchase equity in Tonglian Jinfu and related companies, with key transaction details still under negotiation [8] - Filinger reported stock price fluctuations, with the president reducing his holdings by 8,600 shares during a period of abnormal trading activity [2] - Dongfang Guoxin's controlling shareholder reduced their stake by 2.68 million shares, decreasing their total shareholding from 27.06% to 26.82% [3]

公募今年参与定增热情高涨。 公募排排网数据显示，按定增上市日统计，截至8月5日，今年以来共有24家公募机构参与到47家A股公 司定增，合计获配金额达141.98亿元。 按8月5日收盘价统计，当前浮盈金额达46.5亿元，浮盈比例达32.75%。 昊华科技受青睐 从定增获配金额来看，36只个股公募定增获配金额逾1亿元。其中，18只个股公募定增获配1亿至1.99亿 元，9只个股公募定增获配2亿至4.99亿元，还有9只个股公募定增获配金额不低于5亿元。 其中，昊华科技最受公募定增青睐，共有财通基金、大成基金和诺德基金3家公募机构参与到该股定 增，合计获配金额达16.28亿元。 芯原股份紧随其后，吸引到易方达基金、财通基金、诺德基金、诺安基金和国泰基金5家公募机构参与 到该股定增，合计获配金额达12.66亿元。 国联民生排名第三，吸引到财通基金、华宝基金、华商基金和诺德基金4家公募机构参与到该股定增， 合计获配金额达9.16亿元。 此外，迪哲医药、中航沈飞、安宁股份、中钨高新、佰维存储和中远海特6只个股公募定增获配金额均 不低于5亿元。 排排网财富公募产品运营曾方芳对《国际金融报》记者表示，公募积极参与定增，说明公募行 ...

8月6日晚间迪哲医药(688192)发布公告称，公司在研产品DZD8586获美国食品药品监督管理局(下 称"FDA")授予"快速通道认定"("Fast Track Designation")，用于既往接受过至少两线治疗(包括布鲁顿氏 酪氨酸激酶(BTK)抑制剂和BCL-2抑制剂)的复发难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤 (CLL/SLL)。 据了解，"快速通道认定"作为一项加快药物研发与审评的通道，是FDA为了促进用于治疗严重疾病和解 决未满足的治疗需求的新药研发而授予在研药物的一种资格认定。根据FDA指导原则，研发中的新药获 得快速通道认定资格后，有机会享受一系列加速药物开发的政策，从而有望加快新药的研发和上市进 程。 公开资料显示，CLL/SLL患者在接受共价和/或非共价BTK抑制剂和BCL-2抑制剂治疗后，极易复发。复 发难治性CLL/SLL通常由两种耐药机制引发：C481XBTK突变和非BTK依赖性BCR信号通路激活，目前 尚无能同时解决这两种耐药机制的治疗方案。 DZD8586是迪哲医药自主研发的全球首创LYN/BTK双靶点抑制剂，可同时阻断BTK依赖性和非依赖性 BCR信号通路，抑制降解剂 ...

Group 1 - Jerry Holdings reported a net profit of 1.241 billion yuan for the first half of 2025, an increase of 14.04% year-on-year, with total revenue reaching 6.901 billion yuan, up 39.21% year-on-year [1] - Tian Tan Biological announced a net profit of 633 million yuan for the first half of 2025, a decrease of 12.88% year-on-year, with total revenue of 3.110 billion yuan, an increase of 9.47% year-on-year [2] - Shunbo Alloy achieved a net profit of 177 million yuan for the first half of 2025, a significant increase of 110.56% year-on-year, with total revenue of 7.126 billion yuan, up 11.75% year-on-year [7] Group 2 - Dashi Intelligent signed a contract for the Jingpai Building smart project with a total contract value of 34.06 million yuan, accounting for 1.07% of the company's audited revenue for 2024 [3] - Maglev Technology plans to invest 700 million yuan to establish a research and production base for maglev compressors, aiming to optimize product structure and enhance production capacity [4] - Koweil received government subsidies totaling 5.502 million yuan, which are expected to positively impact the company's profits for 2025 [5] Group 3 - Pengding Holdings reported a consolidated revenue of 3.002 billion yuan for July 2025, an increase of 12.28% compared to the same period last year [9] - Liuyou Group repurchased 544,500 shares at a price range of 18.29 to 18.36 yuan per share, totaling approximately 9.9828 million yuan [10] - Jin Xin Nong reported a sales revenue of 96.731 million yuan from pig sales in July 2025, with a total of 79,400 pigs sold [12] Group 4 - Jiangsu Huachen plans to use up to 70 million yuan of idle raised funds for cash management, investing in safe and liquid financial products [13] - Gongtong Pharmaceutical's subsidiary intends to purchase assets from an affiliate for 16.57 million yuan to build a wastewater treatment facility [15] - Tian Shi Li appointed Wang Yimin as the vice general manager, effective immediately [16] Group 5 - Zhejiang Yongqiang established a subsidiary in Indonesia with a registered capital of 230 billion Indonesian rupiah, focusing on overseas capacity investment and international trade [18] - Wangli Security received three invention patents, enhancing its product portfolio in security locks [20] - Shennong Group reported a sales revenue of 327 million yuan from pig sales in July 2025, with an average selling price of 14.73 yuan per kilogram [21] Group 6 - Dize Pharmaceutical's product DZD8586 received fast track designation from the FDA for treating relapsed refractory chronic lymphocytic leukemia [23] - Daqin Railway reported a cargo transportation volume of 31.79 million tons in July 2025, a year-on-year increase of 5.40% [24] - Xin Hongye's subsidiary won a bid for a nuclear-grade cable procurement project worth 81.58 million yuan [26] Group 7 - Hainan Hengbo established a wholly-owned subsidiary with a registered capital of 50 million yuan, focusing on technology services and new material technology research [26] - Changhong Huayi reported a net profit of 257 million yuan for the first half of 2025, an increase of 13.42% year-on-year, with total revenue of 6.628 billion yuan [27] - Haiguang Information achieved a net profit of 1.201 billion yuan for the first half of 2025, an increase of 40.78% year-on-year, with total revenue of 5.464 billion yuan [28] Group 8 - Dongmu Co. reported a net profit of 261 million yuan for the first half of 2025, an increase of 37.61% year-on-year, with total revenue of 2.930 billion yuan [29] - Hanma Technology announced the resignation of its executive vice president due to personal reasons [30] - Guangge Technology's shareholders plan to reduce their holdings by up to 4.04% of the company's shares [31] Group 9 - *ST Energy's subsidiary won a bid for an independent energy storage project with a total bid price of 320 million yuan for design and 301 million yuan for construction [32] - Chipeng Micro plans to reduce its holdings by up to 2% of the company's shares due to personal financial needs [33] - Ancar Detection announced a change in its controlling shareholder to Silicon Technology, with stock resuming trading [35] Group 10 - Dahao Technology's vice president is temporarily unable to perform duties due to health reasons [36] - Sanjiang Shopping's cooperation agreement with Hema will not be renewed after its expiration in March 2026 [37] - Huisheng Biological reported a net profit of 117 million yuan for the first half of 2025, a year-on-year increase of 325.88% [38] Group 11 - Dongshan Precision plans to increase capital in its subsidiary by 3.5 billion USD to support high-end PCB projects [39] - Yunnan Copper's subsidiary's bankruptcy liquidation application has been accepted by the court due to resource depletion [40] - Shanghai Bank's board member and chairman's qualifications have been approved by regulatory authorities [41] Group 12 - Junwei Electronics plans to acquire 100% of Flat Electronics Co., Ltd. for 2.6 billion yen to enter the film resistor market [42] - Daodaoquan's controlling shareholder plans to increase its stake in the company by 50 million to 100 million yuan [43] - Yinglian Co.'s subsidiary signed a strategic cooperation agreement with a well-known cylindrical battery company [45] Group 13 - Debang Technology's state integrated circuit fund plans to reduce its holdings by up to 3% of the company's shares [47] - Tianyi New Materials plans to sell part of its subsidiary's assets for 51.4 million yuan to improve cash flow [49] - Rongtai Co. intends to acquire 51% of Zhongshan Aoduo for 288 million yuan [51]

证券代码：688192 证券简称：迪哲医药 公告编号：2025-49 迪哲（江苏）医药股份有限公司 自愿披露关于 DZD8586 获美国 FDA 快速通道认定的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 三、风险提示 由于研发药品具有高科技、高风险、高附加值的特点，药品从研发到上市周 期长、环节多，存在诸多不确定因素，目前上述产品尚处于临床试验阶段，临床 试验结果能否支持药品上市申请、能否最终获得上市批准以及何时获得上市批准 尚存在不确定性，敬请广大投资者注意防范投资风险。 公司将按相关规定及时对后续进展情况履行信息披露义务，有关公司信息以 上海证券交易所网站以及公司指定披露媒体《上海证券报》《证券时报》《证券 日报》刊登的公告为准。 近日，迪哲（江苏）医药股份有限公司（以下简称"公司"）在研产品 DZD8586 获美国食品药品监督管理局（以下简称"FDA"）授予"快速通道认定"（"Fast Track Designation"）用于既往接受过至少两线治疗（包括布鲁顿氏酪氨酸激酶 （BTK）抑制剂和 BCL-2 抑 ...